Your browser doesn't support javascript.
loading
Neuroimaging in moderate MDMA use: A systematic review.
Mueller, F; Lenz, C; Steiner, M; Dolder, P C; Walter, M; Lang, U E; Liechti, M E; Borgwardt, S.
Afiliação
  • Mueller F; Department of Psychiatry (UPK), University of Basel, Switzerland.
  • Lenz C; Department of Psychiatry (UPK), University of Basel, Switzerland.
  • Steiner M; Department of Psychiatry (UPK), University of Basel, Switzerland.
  • Dolder PC; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Switzerland.
  • Walter M; Department of Psychiatry (UPK), University of Basel, Switzerland.
  • Lang UE; Department of Psychiatry (UPK), University of Basel, Switzerland.
  • Liechti ME; Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Switzerland.
  • Borgwardt S; Department of Psychiatry (UPK), University of Basel, Switzerland. Electronic address: stefan.borgwardt@upkbs.ch.
Neurosci Biobehav Rev ; 62: 21-34, 2016 Mar.
Article em En | MEDLINE | ID: mdl-26746590
ABSTRACT
MDMA ("ecstasy") is widely used as a recreational drug, although there has been some debate about its neurotoxic effects in humans. However, most studies have investigated subjects with heavy use patterns, and the effects of transient MDMA use are unclear. In this review, we therefore focus on subjects with moderate use patterns, in order to assess the evidence for harmful effects. We searched for studies applying neuroimaging techniques in man. Studies were included if they provided at least one group with an average of <50 lifetime episodes of ecstasy use or an average lifetime consumption of <100 ecstasy tablets. All studies published before July 2015 were included. Of the 250 studies identified in the database search, 19 were included. There is no convincing evidence that moderate MDMA use is associated with structural or functional brain alterations in neuroimaging measures. The lack of significant results was associated with high methodological heterogeneity in terms of dosages and co-consumption of other drugs, low quality of studies and small sample sizes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Drogas Ilícitas / N-Metil-3,4-Metilenodioxianfetamina / Transtornos Relacionados ao Uso de Anfetaminas / Neuroimagem / Alucinógenos Tipo de estudo: Systematic_reviews Limite: Animals / Humans Idioma: En Revista: Neurosci Biobehav Rev Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Encéfalo / Drogas Ilícitas / N-Metil-3,4-Metilenodioxianfetamina / Transtornos Relacionados ao Uso de Anfetaminas / Neuroimagem / Alucinógenos Tipo de estudo: Systematic_reviews Limite: Animals / Humans Idioma: En Revista: Neurosci Biobehav Rev Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Suíça